/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $113.5 billion, the company focuses on products and experimental therapies address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.
Shares of this biopharma giant have underperformed the broader market considerably over the past year. BMY has gained 4.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 35.8%. In 2024, BMY stock is up 7.7%, compared to the SPX’s 24.3% rise on a YTD basis.